Jane Street Group LLC Has $846,000 Stake in Embecta Corp. (NASDAQ:EMBC)

Jane Street Group LLC lowered its position in Embecta Corp. (NASDAQ:EMBC - Free Report) by 76.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 40,959 shares of the company's stock after selling 135,528 shares during the quarter. Jane Street Group LLC owned 0.07% of Embecta worth $846,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Principal Financial Group Inc. grew its position in shares of Embecta by 2.9% during the 4th quarter. Principal Financial Group Inc. now owns 280,004 shares of the company's stock valued at $5,782,000 after buying an additional 7,887 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Embecta by 0.7% in the 4th quarter. Bank of New York Mellon Corp now owns 685,493 shares of the company's stock valued at $14,155,000 after acquiring an additional 4,769 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in shares of Embecta in the 4th quarter valued at approximately $209,000. Smartleaf Asset Management LLC increased its stake in Embecta by 175.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,216 shares of the company's stock valued at $25,000 after buying an additional 774 shares during the period. Finally, Victory Capital Management Inc. increased its stake in Embecta by 5.6% in the 4th quarter. Victory Capital Management Inc. now owns 17,489 shares of the company's stock valued at $361,000 after buying an additional 923 shares during the period. Institutional investors and hedge funds own 93.83% of the company's stock.

Analysts Set New Price Targets

Several research firms have weighed in on EMBC. Mizuho dropped their price objective on shares of Embecta from $15.00 to $13.00 and set a "neutral" rating on the stock in a research note on Friday, May 23rd. BTIG Research set a $25.00 price target on shares of Embecta and gave the stock a "buy" rating in a research note on Friday, May 23rd. Finally, Wall Street Zen upgraded shares of Embecta from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd.

Embecta Price Performance

NASDAQ:EMBC traded down $0.10 during midday trading on Thursday, reaching $10.45. The stock had a trading volume of 798,503 shares, compared to its average volume of 466,729. Embecta Corp. has a 1-year low of $10.27 and a 1-year high of $21.48. The firm's fifty day simple moving average is $11.94 and its 200-day simple moving average is $15.43. The stock has a market capitalization of $610.73 million, a P/E ratio of 10.45, a PEG ratio of 0.78 and a beta of 1.24.

Embecta (NASDAQ:EMBC - Get Free Report) last posted its earnings results on Friday, May 9th. The company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.66 by $0.04. Embecta had a net margin of 5.25% and a negative return on equity of 19.22%. The business had revenue of $259.00 million for the quarter, compared to analyst estimates of $261.77 million. During the same period last year, the business posted $0.67 EPS. Embecta's revenue was down 9.8% compared to the same quarter last year. On average, equities research analysts anticipate that Embecta Corp. will post 2.85 earnings per share for the current fiscal year.

Embecta Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Wednesday, May 28th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 5.74%. The ex-dividend date is Wednesday, May 28th. Embecta's dividend payout ratio (DPR) is presently 66.67%.

Insider Transactions at Embecta

In other Embecta news, Director David F. Melcher acquired 10,000 shares of Embecta stock in a transaction dated Friday, May 23rd. The stock was bought at an average cost of $10.60 per share, with a total value of $106,000.00. Following the acquisition, the director now owns 86,681 shares of the company's stock, valued at approximately $918,818.60. The trade was a 13.04% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.42% of the stock is owned by insiders.

Embecta Profile

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.